After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
Felmetatug vedotin’s exit could be bad news for Mersana.
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
AstraZeneca bags three of the month’s four oncology approvals.
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
